Prelim Results and publication of Annual Report

AI SummaryClose X

Allergy Therapeutics plc reported stable financial performance for the year ended June 30, 2025, with revenue of £55.0 million, broadly flat compared to the previous year, though constant currency revenue grew over 2%. The company experienced an operating loss of £28.2 million, an improvement from £35.3 million in 2024, and an Adjusted EBITDA loss of £9.0 million. Significant post-period events include the full repayment of shareholder loan liabilities and the securing of a new £50 million unsecured shareholder loan facility, alongside continued progress in R&D programs and exploration of a dual primary listing in Hong Kong.

Disclaimer*

UK 100

Latest directors dealings